Ipsen initiates trial of Elafibranor for Primary Biliary Cholangitis in patients intolerant to UDCA
A new clinical trial is underway to evaluate the efficacy of Elafibranor in patients with Primary Biliary Cholangitis who have not responded adequately to Ursodeoxycholic Acid.